Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Multiple myeloma gammopathies

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma

Leukemia volume 33, pages 1291–1296 (2019)Cite this article

Subjects

In a phase I clinical trial of venetoclax in patients with t(11;14) relapsed/refractory multiple myeloma (MM), 40% of the patients treated achieved an objective response [1]. While this response rate with a single agent in MM is impressive, it demonstrates that t(11;14) is not an optimal biomarker for response to venetoclax. Functional profiling of BCL2 family members has been shown to predict responses to therapy in myeloma and other diseases [2]. Therefore, we set out to determine how ex vivo sensitivity to venetoclax corresponds to clinical response and resistance.

The samples appeared to cluster into three groups based on sensitivity. Thirty of the 76 total samples (39.5%) had an IC50 of 100 nM or less (Fig. 1b, green bars), consisting primarily from t(11;14)-positive samples (73.3%). A second cohort of 20 samples (26.3%) had an IC50 from 170 to 450 nM (Fig. 1b, yellow bars). In the remaining 26 samples (34.2%), the IC50 was 900 nM or greater (range 900−18,400 nM, Fig. 1b, red bars). The presence of t(11;14) was the only significant difference between the sensitive group and the others (Supplemental Table 2). Twenty patients received venetoclax as a single agent (n = 10) or in combination with dexamethasone (n = 9) or daratumamab/dexamethasone (n = 1) and 18 had ex vivo sensitivity tested immediately prior to venetoclax treatment (Supplemental Tables 1 and 3). A patient with nonsecretory disease and another that withdrew consent prior to completing one cycle were not included in this analysis. Ten of the 16 remaining patients had a clinical response (partial response (PR) or better), nine of which were in the most sensitive cohort. Only one of the six nonresponding patients was in the most sensitive group (Fig. 1c). Thus, the sensitivity of the assay is 0.9 while the specificity is 0.83 (Fisher’s exact test, P = 0.0076). Examples of ex vivo concentration−response curves and clinical responses are provided in Supplemental Figure 1. Together these data suggest that ex vivo pretreatment sensitivity can predict patient responses to venetoclax.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401–9.

    Article  CAS  Google Scholar 

  2. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334:1129–33.

    Article  Google Scholar 

  3. Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28:210–2.

    Article  CAS  Google Scholar 

  4. Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S, et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016;30:1086–93.

    Article  CAS  Google Scholar 

  5. Kaufman JL, Gasparetto CJ, Mikhael J, Moreau P, Touzeau C, Vij R, et al. Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed/refractory multiple myeloma. Blood. 2017;130:3131.

    Article  Google Scholar 

  6. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15:747–56.

    Article  CAS  Google Scholar 

  7. Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017;23:1028–35.

    Article  CAS  Google Scholar 

  8. Cheng ML, Solit DB. Opportunities and challenges in genomic sequencing for precision cancer care. Ann Intern Med. 2018;168:221–2.

    Article  Google Scholar 

  9. Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018;15:183–92.

    Article  Google Scholar 

  10. Leverson JD. Chemical parsing: dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors. Mol Cell Oncol. 2016;3:e1050155.

    Article  Google Scholar 

  11. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117:112–21.

    Article  Google Scholar 

  12. Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30:761–4.

    Article  CAS  Google Scholar 

  13. Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maiga S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118:3901–10.

    Article  CAS  Google Scholar 

  14. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91–101.

    Article  CAS  Google Scholar 

  15. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28:384–90.

    Article  Google Scholar 

  16. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160:977–89.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the patients for providing the samples used in this study. They also acknowledge the hard work and dedication of the Winship Myeloma Research Team for consenting patients and collecting samples. Funding was provided by R01 CA192844, P30 CA138292 and the Emory Myeloma Working Group.

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Emory University School of Medicine and the Winship Cancer Institute of Emory University, Atlanta, GA, USA

    Shannon M. Matulis, Vikas A. Gupta, Leonard T. Heffner Jr., Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman & Lawrence H. Boise

  2. Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada

    Paola Neri & Nizar J. Bahlis

  3. Oncology Development, Abbvie, North Chicago, IL, USA

    Paulo Maciag & Joel D. Leverson

Authors
  1. Shannon M. Matulis
    View author publications

    Search author on:PubMed Google Scholar

  2. Vikas A. Gupta
    View author publications

    Search author on:PubMed Google Scholar

  3. Paola Neri
    View author publications

    Search author on:PubMed Google Scholar

  4. Nizar J. Bahlis
    View author publications

    Search author on:PubMed Google Scholar

  5. Paulo Maciag
    View author publications

    Search author on:PubMed Google Scholar

  6. Joel D. Leverson
    View author publications

    Search author on:PubMed Google Scholar

  7. Leonard T. Heffner Jr.
    View author publications

    Search author on:PubMed Google Scholar

  8. Sagar Lonial
    View author publications

    Search author on:PubMed Google Scholar

  9. Ajay K. Nooka
    View author publications

    Search author on:PubMed Google Scholar

  10. Jonathan L. Kaufman
    View author publications

    Search author on:PubMed Google Scholar

  11. Lawrence H. Boise
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Lawrence H. Boise.

Ethics declarations

Conflict of interest

NJB, funding and honorarium from Celgene and Janssen; PM and JDL, employment, Abbvie; LTH, research funding, Abbvie; SL, consultancy, Takeda, Celgene, Novartis, Abbvie, Amgen, Janssen, Bristol-Myers Squibb; AKN, advisory board or consultancy, Amgen, Adaptive Technologies, Janssen, Celgene, Spectrum Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Takeda; JLK, Consultancy, Abbvie, Janssen, Bristol-Myers Squibb, Takeda, Data Monitoring Committee, Karyopharm, Pharmacyclics; LHB, consultancy, Abbvie, honorarium, AstraZeneca. The other authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matulis, S.M., Gupta, V.A., Neri, P. et al. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia 33, 1291–1296 (2019). https://doi.org/10.1038/s41375-018-0374-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41375-018-0374-8

This article is cited by

Search

Advanced search

Quick links